Late-breaking results from the Phase III NRG GY019 trial indicate that letrozole monotherapy (L) did not demonstrate ...

Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groupsAzenosertib ...

Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial. Spravato ...

Advanced disease progression occurred less often with vutrisiran than placebo in both the overall population (8.0% vs 10.7%) ...

NRG-GY019 backs current LGSOC standard care; endocrine therapy alone promising in some pat ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

The efficacy of P2Y12 monotherapy depends on the type of drug used after discontinuation of dual antiplatelet therapy (DAPT) for post-PCI patients, according to a new patient-level meta-analysis.

Please provide your email address to receive an email when new articles are posted on . Dolutegravir monotherapy was safe and noninferior vs. combination ART. Switching to monotherapy from combination ...

The benefits of limiting dual antiplatelet therapy (DAPT) to a short course after PCI for acute coronary syndromes vary depending on the type of monotherapy used afterward, according to a new network ...

The update removes the requirement for Leqvio to be used as an adjunct to statin therapy. The Food and Drug Administration (FDA) has approved a labeling update for Leqvio ® (inclisiran) allowing for ...

Many patients with chronic lymphocytic leukemia (CLL) are treated with two- or three-drug regimens, but for some patients just one drug may be enough. Particularly for older patients or those who are ...